Pseudomyxoma peritonei from an ovarian mucinous cystadenoma mimicking ovarian cancer

Authors

  • Lamyae Errami Department of Gynecology-Obstetrics and Reproductive Medicine, Mohammed VI University Hospital, Oujda, Morocco
  • Hajar Jakhjoukh Department of Gynecology-Obstetrics and Reproductive Medicine, Mohammed VI University Hospital, Oujda, Morocco
  • Hafsa Taheri Department of Gynecology-Obstetrics and Reproductive Medicine, Mohammed VI University Hospital, Oujda, Morocco
  • Hanane Saadi Department of Gynecology-Obstetrics and Reproductive Medicine, Mohammed VI University Hospital, Oujda, Morocco
  • Ahmed Mimouni Department of Gynecology-Obstetrics and Reproductive Medicine, Mohammed VI University Hospital, Oujda, Morocco

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20261287

Keywords:

Pseudomyxoma peritonei, Ovarian mucinous cystadenoma, Ovarian tumor, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Gelatinous ascites, Peritoneal carcinomatosis

Abstract

Pseudomyxoma peritonei (PMP) is a rare, borderline malignant condition, most commonly originating from the appendix, with ovarian origin being extremely rare. Rupture of ovarian mucinous tumours can result in dissemination of gelatinous mucus and tumour cells throughout the peritoneal cavity, leading to accumulation of ascites. We report a 56-year-old grand multiparous woman presenting with chronic abdominal pain and progressive distension. Physical examination revealed stable vital signs and overweight status (BMI 27 kg/m²). Laboratory investigations showed mild anaemia, and preoperative serum tumor markers (CA-125, CEA, CA 19-9) were evaluated. Imaging revealed a large multiloculated pelvi-abdominal cystic mass (22×19 cm) with massive ascites and peritoneal calcifications, suggestive of ovarian malignancy. An exploratory laparotomy revealed a 20 cm left ovarian mass with solid and multiloculated gelatinous components, with an appendix slightly enlarged, while the right adnexa and the uterus were unremarkable. Accidental intraoperative rupture released approximately 3 liters of gelatinous ascites. The patient underwent left salpingo-oophorectomy, appendectomy, multiple peritoneal biopsies, and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). Histopathology confirmed PMP originating from an ovarian mucinous cystadenoma.The patient remains under regular surveillance. Complete cytoreductive surgery with HIPEC offers the best prognosis, though long-term follow-up is essential due to the risk of recurrence. Ovarian-origin PMP is rare and may mimic advanced ovarian malignancy. Accurate diagnosis relies on histopathology, and management requires complete cytoreduction combined with HIPEC, with vigilant long-term follow-up.

References

Fonseca C, Carvalho S, Cunha TM, Gil RT, Abecasis N. The many faces of pseudomyxoma peritonei: a radiological review based on 30 cases. Radiol Bras. 2019;52(6):372-7.

Tsoukalas N, Tsapakidis K, Tolia M, Kiakou M, Galanopoulos M, Aravantinou-Fatorou E, et al. Pseudomyxoma peritonei: a challenging clinical diagnosis. Case report and review of the literature. Cancer Diagn Progn. 2024;4:198.

Taher R, Gray D, Ramage J. The quality of life of pseudomyxoma peritonei patients: a scoping review. Eur J Cancer Care. 2024;33:e8137209.

Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, Kusamura S, et al. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. 2021;47(1):11-35.

Tsai CJ. Ultrasound features of disseminated adenomucinosis (pseudomyxoma). Br J Radiol. 1998;71(845):564-6.

Rodríguez LR, García NF, Salazar DJT, Illán RG, Sánchez TBD. Imaging findings for mucinous tumors of the abdomen and pelvis. Radiologia. 2019;61(5):370-87.

Rizvi SA, Syed W, Shergill R. Approach to pseudomyxoma peritonei. World J Gastrointest Surg. 2018;10(3):49-56.

Liang L, Han X, Zhou N, Xu H, Guo J, Zhang Q. Ultrasound for preoperatively predicting pathology grade, complete cytoreduction possibility, and survival outcomes of pseudomyxoma peritonei. Front Oncol. 2021;11:690178.

Ye S, Zheng S. Comprehensive understanding and evolutional therapeutic schemes for pseudomyxoma peritonei: a literature review. Am J Clin Oncol. 2022;45(5):223-31.

Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15(1):49-58.

Mercier F, Dagbert F, Pocard M, Lenne X, Goéré D, Quenet F, et al. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: patterns and timing of recurrence. BJS Open. 2019;3(2):195-202.

Kaur H, Litinas MC, Lauder C, Da Silva N, Bradshaw EL, Price T, et al. Long-term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a 22-year single institution experience. ANZ J Surg. 2025;95(10):2112-22.

Downloads

Published

2026-04-28

How to Cite

Errami, L., Jakhjoukh, H., Taheri, H., Saadi, H., & Mimouni, A. (2026). Pseudomyxoma peritonei from an ovarian mucinous cystadenoma mimicking ovarian cancer. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 15(5), 1788–1791. https://doi.org/10.18203/2320-1770.ijrcog20261287

Issue

Section

Case Reports